Amgen seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.
Amgen Inc. launched its first outcomes-based contract for Enbrel (etanercept) in the US with Harvard Pilgrim Health Care earlier this year as it seeks to defend its blockbuster against heightened pressure from payers and new competition.
The two-year contract went into effect on Jan. 1 and is based on an "effectiveness algorithm" driven by six criteria,...
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
